Efficacy and Safety of HIP1601 Capsule

Inclusion Criteria: * 19≤ age ≤ 75 * Esophago-Gastro-Duodenoscopy LA classification ≥ grade A * Patients experienced heartburn or acid regurgitation within 7 days of screening day * Patients understood the consents and purpose of this trial and signed consent form Exclusion Criteria: * Has malignancy in the upper gastrointestinal tract, digestive ulcer, bleeding disorder or signs of gastrointestinal bleeding * Has a severe liver disorder(at screening day, AST or ALT level exceeds 3 times more than normal upper range) * Has a clinically significant renal failure(at screening day, MDRD eGFP ≤ 59 mL/min/1.73m2 or Serum creatinine \>2.0mg/dL) * Uncontrolled diabetes mellitus * Before screening EGD, a patient who has taken H2-receptor antagonist or PPI within 2 weeks * Before screening EGD, a patient who has taken drugs containing following list within 1 weeks : warfarin, anticholinergics for spasmolytic GI, antineoplastic agents, salicylates(except 100mg a day for prevention of cardiovascular disease), steroids, propulsives, sucralfate, NSAIDs, other antacids(e.g. antacids of prostaglandin analogs, antacids of aluminum/magnesium)